Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT02383212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Study identification
- NCT ID
- NCT02383212
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 398 participants
Conditions and interventions
Conditions
Interventions
- Cemiplimab Drug
- Hypofractionated radiotherapy Radiation
- Cyclophosphamide Drug
- Docetaxel Drug
- Carboplatin Drug
- GM-CSF Drug
- Paclitaxel Drug
- Pemetrexed Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2015 (Actual)
- Primary completion
- Nov 18, 2019 (Actual)
- Completion
- Nov 18, 2019 (Actual)
- Last update posted
- Jan 27, 2020
2015 – 2019
United States locations
- U.S. sites
- 40
- U.S. states
- 25
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | — | — |
| Western Regional Medical Center | Goodyear | Arizona | — | — |
| Mayo Clinic | Phoenix | Arizona | — | — |
| University of Arizona Cancer Center | Tucson | Arizona | — | — |
| City of Hope National Medical Center | Duarte | California | — | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | — | — |
| Stanford University | Stanford | California | — | — |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | — | — |
| Norwalk Hospital | Norwalk | Connecticut | — | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | — | — |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | — | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | — | — |
| University of Chicago | Chicago | Illinois | — | — |
| Indiana University | Indianapolis | Indiana | — | — |
| University of Kansas Cancer Center | Fairway | Kansas | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | — | — |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | — | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | — | — |
| Hackensack University Medical Center | Hackensack | New Jersey | — | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Laura & Isaac Perlmutter Cancer Center | New York | New York | — | — |
| Mount Sinai Medical Center | New York | New York | — | — |
| Weill Cornell Medical College | New York | New York | — | — |
| Duke Cancer Institute | Durham | North Carolina | — | — |
| University Hospitals Case Medical Center | Cleveland | Ohio | — | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | — | — |
| Providence Portland Medical Center | Portland | Oregon | — | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | — | — |
| University of Pittsburgh Medical Center Shadyside | Pittsburgh | Pennsylvania | 15232 | — |
| Miriam Hospital | Providence | Rhode Island | — | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | — | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | — | — |
| Mary Crowley Cancer Research Center - Medical City | Dallas | Texas | — | — |
| Baylor College of Medicine | Houston | Texas | — | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | — | — |
| START South Texas Accelerated Research Therapeutics | San Antonio | Texas | — | — |
| Northwest Medical Specialties | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02383212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2020 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02383212 live on ClinicalTrials.gov.